Literature DB >> 32054668

Cognitive inhibition impairments in presymptomatic C9orf72 carriers.

Isabelle Le Ber1,2,3,4, Raffaella Migliaccio5,2,3,4, Maxime Montembeault1,2,3,6, Sabrina Sayah1, Daisy Rinaldi1,4, Benjamin Le Toullec1,4, Anne Bertrand2,7,8, Aurélie Funkiewiez4,9, Dario Saracino1,4,8, Agnès Camuzat1, Philippe Couratier10,11, Marianne Chouly10,11, Didier Hannequin12,13, Carole Aubier-Girard12,13, Florence Pasquier14, Xavier Delbeuck14, Olivier Colliot1,8, Bénédicte Batrancourt1,2,3, Carole Azuar1,3,4, Richard Lévy1,2,3,4, Bruno Dubois1,2,4.   

Abstract

OBJECTIVE: To investigate cognitive inhibition in presymptomatic C9orf72 mutation carriers (C9+) and its associated neuroanatomical correlates.
METHODS: Thirty-eight presymptomatic C9orf72 mutation carriers (C9+, mean age 38.2±8.0 years) and 22 C9- controls from the PREV-DEMALS cohort were included in this study. They underwent a cognitive inhibition assessment with the Hayling Sentence Completion Test (HSCT; time to completion (part B-part A); error score in part B) as well as a 3D MRI.
RESULTS: C9+ individuals younger than 40 years had higher error scores (part B) but equivalent HSCT time to completion (part B-part A) compared to C9- individuals. C9+ individuals older than 40 years had both higher error scores and longer time to completion. HSCT time to completion significantly predicted the proximity to estimated clinical conversion from presymptomatic to symptomatic phase in C9+ individuals (based on the average age at onset of affected relatives in the family). Anatomically, we found that HSCT time to completion was associated with the integrity of the cerebellum.
CONCLUSION: The HSCT represents a good marker of cognitive inhibition impairments in C9+ and of proximity to clinical conversion. This study also highlights the key role of the cerebellum in cognitive inhibition. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  C9orf72 mutation; cerebellum; cognitive inhibition; hayling sentence completion test; voxel-based morphometry

Year:  2020        PMID: 32054668     DOI: 10.1136/jnnp-2019-322242

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  7 in total

Review 1.  The imaging signature of C9orf72 hexanucleotide repeat expansions: implications for clinical trials and therapy development.

Authors:  Stacey Li Hi Shing; Mary Clare McKenna; We Fong Siah; Rangariroyashe H Chipika; Orla Hardiman; Peter Bede
Journal:  Brain Imaging Behav       Date:  2021-01-05       Impact factor: 3.978

2.  Clinical Update on C9orf72: Frontotemporal Dementia, Amyotrophic Lateral Sclerosis, and Beyond.

Authors:  Dario Saracino; Isabelle Le Ber
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Plasma microRNA signature in presymptomatic and symptomatic subjects with C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis.

Authors:  Virgilio Kmetzsch; Vincent Anquetil; Dario Saracino; Daisy Rinaldi; Agnès Camuzat; Thomas Gareau; Ludmila Jornea; Sylvie Forlani; Philippe Couratier; David Wallon; Florence Pasquier; Noémie Robil; Pierre de la Grange; Ivan Moszer; Isabelle Le Ber; Olivier Colliot; Emmanuelle Becker
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-11-25       Impact factor: 10.154

4.  Frontotemporal dementia subtypes based on behavioral inhibition deficits.

Authors:  Valérie Godefroy; Delphine Tanguy; Arabella Bouzigues; Idil Sezer; Johan Ferrand-Verdejo; Carole Azuar; David Bendetowicz; Guilhem Carle; Armelle Rametti-Lacroux; Stéphanie Bombois; Emmanuel Cognat; Pierre Jannin; Xavier Morandi; Isabelle Le Ber; Richard Levy; Bénédicte Batrancourt; Raffaella Migliaccio
Journal:  Alzheimers Dement (Amst)       Date:  2021-04-06

5.  Structural MRI Signatures in Genetic Presentations of the Frontotemporal Dementia/Motor Neuron Disease Spectrum.

Authors:  Edoardo Gioele Spinelli; Alma Ghirelli; Silvia Basaia; Camilla Cividini; Nilo Riva; Elisa Canu; Veronica Castelnovo; Teuta Domi; Giuseppe Magnani; Francesca Caso; Paola Caroppo; Sara Prioni; Giacomina Rossi; Lucio Tremolizzo; Ildebrando Appollonio; Vincenzo Silani; Paola Carrera; Massimo Filippi; Federica Agosta
Journal:  Neurology       Date:  2021-09-20       Impact factor: 9.910

Review 6.  Biomarkers for C9orf7-ALS in Symptomatic and Pre-symptomatic Patients: State-of-the-art in the New Era of Clinical Trials.

Authors:  Giorgia Querin; Maria Grazia Biferi; Pierre-Francois Pradat
Journal:  J Neuromuscul Dis       Date:  2022

Review 7.  Cognitive and behavioural inhibition deficits in neurodegenerative dementias.

Authors:  Raffaella Migliaccio; Delphine Tanguy; Arabella Bouzigues; Idil Sezer; Bruno Dubois; Isabelle Le Ber; Bénédicte Batrancourt; Valérie Godefroy; Richard Levy
Journal:  Cortex       Date:  2020-08-10       Impact factor: 4.027

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.